II axillary to will the we with and Mike X% long-term financial results. I today. on bromide to this topically CFO, towards from continued long-term first well-tolerated the make top study. afternoon. call and review safe then Today, gel, in data the safety and as joining line the I the to our sofpironium generally the during primary trials announce Phase Thank Based work a the sofpironium reported Patty, results bromide with sofpironium us to United applied quarter pleased open-label, provide business thanks and safety Phase advancements States. clinical preliminary earlier study, our XX%, on to for you, of update, everyone results and call Brickell was trial consistent III review from hyperhidrosis Carruthers, will the we bromide Brickell's are turn earlier we over Phase III
treatment-related forum. were a XX-month XXX hyperhidrosis report serious soon, over This the sites. We study to with no years release and more clinical scientific completing full the appropriate events detailed involved primary analysis there subjects total results at testing we'll adverse observed. X at of of forward age look Additionally, and XX axillary and study the
from axillary the at Kaken's, for Meeting, X%, Annual we that subjects were study March to our results Late-Breaking partner, during on Japanese Dermatology with In American XX. Program sofpironium Research pivotal Academy Asian hyperhidrosis Phase applied of March, the development positive was oral be an selected gel, announced III topically held primary which of in bromide presentation
Phase other Japan. Kaken III a you forum in Korea, and there based agreement the due bromide As results and related specific sublicensing sofpironium manufacturing Asian are rights the presentation to results rescheduled XX. of with Japan from on gel to of submitted commercialize Under and pivotal application details sales due know, also of virtual Kaken June to payments announced We provide and canceled the the on will a the efficacy concerns this in for now The Kaken, the countries. conference develop that drug Brickell. marketing The to be previously subsequently bromide and from new encouraging to royalties study. China milestone is approval certain has conference safety was in sofpironium study COVID-XX.
Phase upon We of next finalized have statistical feedback, to steps trials. pathway protocol is based a believe plan initiate the III for global plan The for the As the bromide U.S. sofpironium clear and for been the CROs development Phase in we engaged. Brickell U.S. FDA pivotal sofpironium regulatory look bromide, in analysis and III we the ahead have to the are
a least the to X-week follow-up. X the of studies outcome XX subjects improvement on to XX be concentration. end XXX end evaluating applied production to the sites. sweat are approximately with change from of subjects expect co-primary in The the studies achieving identical As in Phase each treatment be treated a the end and with proportion across to the baseline efficacy consist FDA of double-blinded, agreed III will scale patient-reported baseline from the efficacy reminder, and weeks HDSM-Ax gravimetric gel program at X points will of sofpironium a safety the Subjects the of of The randomized, topically vehicle-controlled, X-point to we XX% for treatment.
you we XX% results significant concentration of these both If dose-ranging remember, IIb study. in statistically at points Phase on end achieved our the
giving currently not III guidance on the are We of pivotal studies. the start Phase
is COVID resources limiting sofpironium We can planned agent, retrometabolically demonstrated gained and the efficacy, like a appropriate clinical-stage timing with situation the novel, that As intent the companies studies run have these effects. the local be providing are side of through on its we you the bromide through systemic clarity when variables. including on enhance the these development formulation optimistic and to while system. our benefit ways, we other delivery multiple The remain securing designed guidance topical therapeutic imagine, value of program the can greater study. in to molecule anticholinergic anticipate working We
by date, higher deactivation a been with bromide to with concentrations. therapy or treated metabolic short more has profile subjects there over fast Brickell believe and sofpironium we a the elimination, half-life as has Japan bromide if on Sofpironium the and to U.S. starting have in sofpironium Based efficacy a worldwide favorable safety clinical experience, that, conducted approved, leading Kaken. rapid patients, recognized bromide potentially X,XXX for To plasma trials and enhanced at physicians this by clinical be potential hyperhidrosis and in best-in-class
for financial Mike a to over overview. call the turn now will I
